share_log

歌禮製藥-B：翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 19 05:43
Summary by Moomoo AI
歌禮製藥有限公司於2024年2月19日提交了翌日披露報表，披露了自2023年12月19日至2024年2月19日期間，公司進行了多次股份購回但未註銷的情況。根據報表，公司在這段期間內共購回了68,491,000股普通股，佔已發行股份的6.3001%。最後一次購回發生在2024年2月19日，當日購回了246,000股，每股價格為1.84港元，總額為452,640港元。該系列股份購回行動已獲得董事會的正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關規定。
歌禮製藥有限公司於2024年2月19日提交了翌日披露報表，披露了自2023年12月19日至2024年2月19日期間，公司進行了多次股份購回但未註銷的情況。根據報表，公司在這段期間內共購回了68,491,000股普通股，佔已發行股份的6.3001%。最後一次購回發生在2024年2月19日，當日購回了246,000股，每股價格為1.84港元，總額為452,640港元。該系列股份購回行動已獲得董事會的正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關規定。
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 19, 2024, disclosing that the Company conducted multiple share repurchases but no write-offs between December 19, 2023 and February 19, 2024. According to the report, the company repurchased a total of 68,491,000 shares of ordinary shares during this period, representing 6.3001% of the issued shares. The last repurchase took place on 19 February 2024 and repurchased 246,000 shares at a price of HK$1.84 per share for a total of HK$452,640. This series of share repurchases has been formally authorized by the Board of Directors and complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 19, 2024, disclosing that the Company conducted multiple share repurchases but no write-offs between December 19, 2023 and February 19, 2024. According to the report, the company repurchased a total of 68,491,000 shares of ordinary shares during this period, representing 6.3001% of the issued shares. The last repurchase took place on 19 February 2024 and repurchased 246,000 shares at a price of HK$1.84 per share for a total of HK$452,640. This series of share repurchases has been formally authorized by the Board of Directors and complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more